AI Article Synopsis
- Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults in Western countries, and fludarabine (Flu) is a key treatment, though resistance to it can pose challenges.
- Elevated levels of the MCM7 protein in primary CLL cells contribute to replication stress and malignancy; inhibiting MCM7 can enhance the effectiveness of Flu by increasing cancer cell death and reducing DNA repair.
- Combining MCM7 inhibition with Flu treatment may offer a new strategy to overcome resistance to fludarabine in CLL patients.
Article Abstract
Chronic lymphocytic leukemia (CLL) constitutes the largest percentage of adult leukemia cases in Western countries. Classically, fludarabine (Flu) is an effective drug used as a first-line therapy for CLL; however, Flu resistance limits its clinical effect. Minichromosome maintenance (MCM) complex components 2-7 exert important functions in maintaining genomic stability. Replication stress occurs upon dysregulation of MCM7, which potentiates malignant phenotypes. In this study, primary CLL cells and CLL-derived cell lines displayed elevated MCM7 expression. In CD40-stimulated primary CLL cells, MCM7 inhibition resulted in increased Flu-induced apoptosis and delayed repair of DNA damage. In the MEC-1 and EHEB cell lines, knockdown of MCM7 with lentivirus significantly inhibited cell proliferation and promoted cell cycle arrest at S phase. Moreover, MCM7 silencing sensitized both cell lines to Flu by increasing replication stress. The combination of Flu administration with MCM7 inhibition represents a novel approach to reverse Flu resistance in CLL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2018.1523400 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!